Since Huang et al. gave the evidence that ARID1A emerged as a tumor suppressor in 2007 36, the molecular mechanisms underlying worse outcome in cancer patients with ARID1A expression deficiency have been unveiled gradually14, 17. This evidence concerns the gene ARID1A and neoplasm.